Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
The siliceous frustules of diatoms accumulate in fresh and brackish wetlands and lakes. Some peats and mucks contain a sufficient abundance of frustules such that they can be mined. Most of Florida's diatomaceous earths have been found in the muck of wetlands or lakes. The American Diatomite Corporation, from 1935 to 1946, refined a maximum of 145 tons per year from their processing plant near Clermont, Florida. Muck from several locations in Lake County, Florida was dried and burned (calcined) to produce the diatomaceous earth. It was formerly extracted from Lake Mývatn in Iceland. The commercial deposits of diatomite are restricted to Tertiary or Quaternary periods. Older deposits from as early as the Cretaceous Period are known, but are of low quality. Diatomite deposits rich in fossils have been located in New Zealand, but mining of the Foulden Maar deposits on an industrial scale, for conversion to animal feed, has drawn strong opposition.
===== Tree pod burials ===== Another method of natural burial is being developed to plant the human body in fetal position inside an egg shaped pod. The pod containing the body will form a biodegradable capsule that will not harm the surrounding earth. The biodegradable capsule doubles as a seed which can be customized to grow into either a birch, maple, or eucalyptus tree. The goal of this method is to create parks full of trees that loved ones can walk through and mourn, as opposed to a graveyard full of tombstones. This method aims to return the body to the earth in the most environmentally friendly way possible. The tree pod method originated in the UK but is now becoming a more popular method of burial. The definition of natural burial grounds suggests that people are being buried without any kind of formaldehyde-based embalming fluid or synthetic ingredients, and that the bodies that are being returned to the earth will also be returning nutrients to the environment, in a way that is less expensive than other available burial methods. Not only are tree pods a more cost effective and environmentally friendly way to memorialize loved ones, this method also offers emotional support. The memories of loved ones will be immortalized through the concept of a deceased person having a medium (trees) that will continue to live and grow.
=== Brand names === Dutasteride is sold primarily under the brand name Avodart, but also in combination with tamsulosin under the brand names Combodart, Duodart, and Jalyn. Dutasteride is also available in India in combination with alfuzosin under the brand names Alfusin-D and Dutalfa.
Homeobox protein cut-like 1 is a protein that in humans is encoded by the CUX1 gene (previously CUTL1). This protein is a homeodomain protein. The term "cut" in the name "cut-like 1" derives from the "cut wing" phenotype observed in a mutant of Drosophila melanogaster. In mammals, a CCAAT-displacement activity was originally described in DNA binding assays. The human gene was identified following purification of the CCAAT-displacement protein (CDP) and has been successively been called CDP, Cut-like 1 (CUTL1), CDP/Cut and finally, CUX1. (Consequently, a literature search for CUX1 fails to bring up many of the earlier studies). Cut homeobox genes are present in all metazoans. In mammals, CUX1 is expressed ubiquitously in all tissues. A second gene, called CUX2, is expressed primarily in neuronal cells.
Dorothy Mary Crowfoot Hodgkin (née Crowfoot; 12 May 1910 – 29 July 1994) was an English chemist who advanced the technique of X-ray crystallography to determine the structure of biomolecules, which became essential for structural biology. She received the 1964 Nobel Prize in Chemistry, and is the only British woman scientist to have been awarded a Nobel Prize. Among her most influential discoveries are the confirmation of the structure of penicillin as previously surmised by Edward Abraham and Ernst Boris Chain; and mapping the structure of vitamin B12, for which in 1964 she became the third woman to win the Nobel Prize in Chemistry. Hodgkin also elucidated the structure of insulin in 1969 after 35 years of work. Hodgkin used the name "Dorothy Crowfoot" until twelve years after marrying Thomas Lionel Hodgkin, when she began using "Dorothy Crowfoot Hodgkin". Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society (when referring to its sponsorship of the Dorothy Hodgkin fellowship), and by Somerville College. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin". The case of her Nobel prize is inscribed 'Crowfoot Hodgkin'.
Sources: en.wikipedia.org
== Literary and cinematic portrayals == Lobotomies have been featured in several literary and cinematic presentations that both reflected society's attitude toward the procedure and, at times, changed it. Writers and filmmakers have played a pivotal role in turning public sentiment against the procedure.
=== Other === Plantar fibromatosis is a relatively uncommon non-malignant thickening of the plantar fascia. Psoriatic arthritis is a type of inflammatory arthritis that may affect the plantar fascia. Plantar fascial rupture/tear is a relatively uncommon painful tearing of the plantar fascia. The tear can be full or partial.
=== (2) Separation and quantification methods === Separation methods are the first step to decomplexify the venom sample, with a common method being reverse‐phase high performance liquid chromatography (RP-HPLC). This method can be applied broadly to nearly all venoms as a crude fractionation method and to detect the peptide bonds found. A less common techniques like 1D/2D gel electrophoresis can also be used in cases of venoms containing heavy, complex peptides (Preferable >10KDa). This means in additions to RP-HPLC, Gel electrophoresis can help identify large molecules (such as enzymes) and to help refine venom prior to further analytical methods. Next, N-terminal sequencing is used to find the amino acid order of the fractionated proteins/peptides starting with the N-terminal end. Furthermore, SDS‐PAGE (Sodium dodecyl sulfate-polyacrylamide gel electrophoresis) can be performed on the isolated proteins from the RP-HPLC to identify proteins of interest before moving on to the identification stage.
Molybdenum carbides, nitride and phosphides can be used for hydrotreatment of rapeseed oil. Ammonium heptamolybdate is used in biological staining. Molybdenum coated soda lime glass is used in CIGS (copper indium gallium selenide) solar cells, called CIGS solar cells. Phosphomolybdic acid is a stain used in thin-layer chromatography and trichrome staining in histochemistry. Molybdenum is added to stainless steel (e.g., AISI 316L hMo) to improve its corrosion resistance, especially in the presence of harmful reduced sulfur species such as sulfide (H2S, HS−, S2−, sulfide stress cracking) and thiosulfate (S2O2−3, pitting corrosion).
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.